Please login to the form below

Not currently logged in
Email:
Password:

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Amgen, Servier heart failure drug clears trial hurdle

Amgen, Servier heart failure drug clears trial hurdle

Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs called cardiac myosin activators, that are designed to increase the duration of cardiac muscle contractility and improve ... Amgen recently started phase 1 trials of

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Deal Watch July 2016 Deal Watch July 2016

    Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and

  • Astellas: Ten years young Astellas: Ten years young

    option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics